Patient characteristics and outcomes in metastatic upper tract urothelial carcinoma after radical nephroureterectomy

The experience of Japanese multi-institutions

Nobuyuki Tanaka, Eiji Kikuchi, Kent Kanao, Kazuhiro Matsumoto, Hiroaki Kobayashi, Yasumasa Miyazaki, Hiroki Ide, Jun Obata, Katsura Hoshino, Suguru Shirotake, Nozomi Hayakawa, Takeo Kosaka, Akira Miyajima, Tetsuo Momma, Ken Nakagawa, Shintaro Hasegawa, Yosuke Nakajima, Mototsugu Oya

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Objectives To investigate oncological outcomes and prognostic factors in patients with upper tract urothelial carcinoma (UTUC) who experienced disease recurrence after radical nephroureterectomy (RNU). Few studies have focused on the clinical courses of patients who experienced disease recurrence after RNU. Patients and Methods A total of 204 UTUC patients who experienced disease recurrence from a retrospective multi-institutional cohort were included in the present study. Associated patient outcomes were analyzed using multivariate analysis. Results The mean time from RNU to first disease recurrence was 15.0 months and ≈90% of patients experienced disease recurrence within the first 3 years after RNU. During a median follow-up of 8.1 month after disease recurrence, 165 patients died from UTUC and five patients died from other causes. In the 204 cohorts, 1- and 3-year cancer-specific survival rates were 40.2% and 9.7%, respectively, and 1- and 3-year overall survival rates were 39.5% and 9.4%, respectively. After disease recurrence, 132 patients underwent systemic chemotherapy, and a subgroup analysis of patients who underwent systemic chemotherapy multivariate analysis showed that performance status, the presence of liver metastasis and the number of recurrence sites were independently prognostic of cancer-specific and overall survival after relapsing. According to three significant variables, 1- and 3-year cancer-specific survival rates were 72.7% and 20.8% in patients with no risk factors, 46.5% and 7.5% in patients with one risk factor, and 26.4% and 4.4% in patients with two or three risk factors, respectively (P < 0.001). Conclusions Most patients died from UTUC within 3 years, even though systemic chemotherapies were administered after relapsing. Multivariate analysis showed that performance status, the presence of liver metastasis and the number of recurrence sites were independently related to poor survival after systemic chemotherapy.

Original languageEnglish
JournalBJU International
Volume112
Issue number2
DOIs
Publication statusPublished - 2013 Jul

Fingerprint

Carcinoma
Recurrence
Drug Therapy
Multivariate Analysis
Survival Rate
Neoplasm Metastasis
Neoplasms
Survival
Liver

Keywords

  • metastasis
  • nephroureterectomy
  • outcome
  • upper urinary tract
  • urothelial carcinoma

ASJC Scopus subject areas

  • Urology

Cite this

Patient characteristics and outcomes in metastatic upper tract urothelial carcinoma after radical nephroureterectomy : The experience of Japanese multi-institutions. / Tanaka, Nobuyuki; Kikuchi, Eiji; Kanao, Kent; Matsumoto, Kazuhiro; Kobayashi, Hiroaki; Miyazaki, Yasumasa; Ide, Hiroki; Obata, Jun; Hoshino, Katsura; Shirotake, Suguru; Hayakawa, Nozomi; Kosaka, Takeo; Miyajima, Akira; Momma, Tetsuo; Nakagawa, Ken; Hasegawa, Shintaro; Nakajima, Yosuke; Oya, Mototsugu.

In: BJU International, Vol. 112, No. 2, 07.2013.

Research output: Contribution to journalArticle

Tanaka, N, Kikuchi, E, Kanao, K, Matsumoto, K, Kobayashi, H, Miyazaki, Y, Ide, H, Obata, J, Hoshino, K, Shirotake, S, Hayakawa, N, Kosaka, T, Miyajima, A, Momma, T, Nakagawa, K, Hasegawa, S, Nakajima, Y & Oya, M 2013, 'Patient characteristics and outcomes in metastatic upper tract urothelial carcinoma after radical nephroureterectomy: The experience of Japanese multi-institutions', BJU International, vol. 112, no. 2. https://doi.org/10.1111/bju.12133
Tanaka, Nobuyuki ; Kikuchi, Eiji ; Kanao, Kent ; Matsumoto, Kazuhiro ; Kobayashi, Hiroaki ; Miyazaki, Yasumasa ; Ide, Hiroki ; Obata, Jun ; Hoshino, Katsura ; Shirotake, Suguru ; Hayakawa, Nozomi ; Kosaka, Takeo ; Miyajima, Akira ; Momma, Tetsuo ; Nakagawa, Ken ; Hasegawa, Shintaro ; Nakajima, Yosuke ; Oya, Mototsugu. / Patient characteristics and outcomes in metastatic upper tract urothelial carcinoma after radical nephroureterectomy : The experience of Japanese multi-institutions. In: BJU International. 2013 ; Vol. 112, No. 2.
@article{0b5672d073244938a88a564f4446b435,
title = "Patient characteristics and outcomes in metastatic upper tract urothelial carcinoma after radical nephroureterectomy: The experience of Japanese multi-institutions",
abstract = "Objectives To investigate oncological outcomes and prognostic factors in patients with upper tract urothelial carcinoma (UTUC) who experienced disease recurrence after radical nephroureterectomy (RNU). Few studies have focused on the clinical courses of patients who experienced disease recurrence after RNU. Patients and Methods A total of 204 UTUC patients who experienced disease recurrence from a retrospective multi-institutional cohort were included in the present study. Associated patient outcomes were analyzed using multivariate analysis. Results The mean time from RNU to first disease recurrence was 15.0 months and ≈90{\%} of patients experienced disease recurrence within the first 3 years after RNU. During a median follow-up of 8.1 month after disease recurrence, 165 patients died from UTUC and five patients died from other causes. In the 204 cohorts, 1- and 3-year cancer-specific survival rates were 40.2{\%} and 9.7{\%}, respectively, and 1- and 3-year overall survival rates were 39.5{\%} and 9.4{\%}, respectively. After disease recurrence, 132 patients underwent systemic chemotherapy, and a subgroup analysis of patients who underwent systemic chemotherapy multivariate analysis showed that performance status, the presence of liver metastasis and the number of recurrence sites were independently prognostic of cancer-specific and overall survival after relapsing. According to three significant variables, 1- and 3-year cancer-specific survival rates were 72.7{\%} and 20.8{\%} in patients with no risk factors, 46.5{\%} and 7.5{\%} in patients with one risk factor, and 26.4{\%} and 4.4{\%} in patients with two or three risk factors, respectively (P < 0.001). Conclusions Most patients died from UTUC within 3 years, even though systemic chemotherapies were administered after relapsing. Multivariate analysis showed that performance status, the presence of liver metastasis and the number of recurrence sites were independently related to poor survival after systemic chemotherapy.",
keywords = "metastasis, nephroureterectomy, outcome, upper urinary tract, urothelial carcinoma",
author = "Nobuyuki Tanaka and Eiji Kikuchi and Kent Kanao and Kazuhiro Matsumoto and Hiroaki Kobayashi and Yasumasa Miyazaki and Hiroki Ide and Jun Obata and Katsura Hoshino and Suguru Shirotake and Nozomi Hayakawa and Takeo Kosaka and Akira Miyajima and Tetsuo Momma and Ken Nakagawa and Shintaro Hasegawa and Yosuke Nakajima and Mototsugu Oya",
year = "2013",
month = "7",
doi = "10.1111/bju.12133",
language = "English",
volume = "112",
journal = "BJU International",
issn = "1464-4096",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Patient characteristics and outcomes in metastatic upper tract urothelial carcinoma after radical nephroureterectomy

T2 - The experience of Japanese multi-institutions

AU - Tanaka, Nobuyuki

AU - Kikuchi, Eiji

AU - Kanao, Kent

AU - Matsumoto, Kazuhiro

AU - Kobayashi, Hiroaki

AU - Miyazaki, Yasumasa

AU - Ide, Hiroki

AU - Obata, Jun

AU - Hoshino, Katsura

AU - Shirotake, Suguru

AU - Hayakawa, Nozomi

AU - Kosaka, Takeo

AU - Miyajima, Akira

AU - Momma, Tetsuo

AU - Nakagawa, Ken

AU - Hasegawa, Shintaro

AU - Nakajima, Yosuke

AU - Oya, Mototsugu

PY - 2013/7

Y1 - 2013/7

N2 - Objectives To investigate oncological outcomes and prognostic factors in patients with upper tract urothelial carcinoma (UTUC) who experienced disease recurrence after radical nephroureterectomy (RNU). Few studies have focused on the clinical courses of patients who experienced disease recurrence after RNU. Patients and Methods A total of 204 UTUC patients who experienced disease recurrence from a retrospective multi-institutional cohort were included in the present study. Associated patient outcomes were analyzed using multivariate analysis. Results The mean time from RNU to first disease recurrence was 15.0 months and ≈90% of patients experienced disease recurrence within the first 3 years after RNU. During a median follow-up of 8.1 month after disease recurrence, 165 patients died from UTUC and five patients died from other causes. In the 204 cohorts, 1- and 3-year cancer-specific survival rates were 40.2% and 9.7%, respectively, and 1- and 3-year overall survival rates were 39.5% and 9.4%, respectively. After disease recurrence, 132 patients underwent systemic chemotherapy, and a subgroup analysis of patients who underwent systemic chemotherapy multivariate analysis showed that performance status, the presence of liver metastasis and the number of recurrence sites were independently prognostic of cancer-specific and overall survival after relapsing. According to three significant variables, 1- and 3-year cancer-specific survival rates were 72.7% and 20.8% in patients with no risk factors, 46.5% and 7.5% in patients with one risk factor, and 26.4% and 4.4% in patients with two or three risk factors, respectively (P < 0.001). Conclusions Most patients died from UTUC within 3 years, even though systemic chemotherapies were administered after relapsing. Multivariate analysis showed that performance status, the presence of liver metastasis and the number of recurrence sites were independently related to poor survival after systemic chemotherapy.

AB - Objectives To investigate oncological outcomes and prognostic factors in patients with upper tract urothelial carcinoma (UTUC) who experienced disease recurrence after radical nephroureterectomy (RNU). Few studies have focused on the clinical courses of patients who experienced disease recurrence after RNU. Patients and Methods A total of 204 UTUC patients who experienced disease recurrence from a retrospective multi-institutional cohort were included in the present study. Associated patient outcomes were analyzed using multivariate analysis. Results The mean time from RNU to first disease recurrence was 15.0 months and ≈90% of patients experienced disease recurrence within the first 3 years after RNU. During a median follow-up of 8.1 month after disease recurrence, 165 patients died from UTUC and five patients died from other causes. In the 204 cohorts, 1- and 3-year cancer-specific survival rates were 40.2% and 9.7%, respectively, and 1- and 3-year overall survival rates were 39.5% and 9.4%, respectively. After disease recurrence, 132 patients underwent systemic chemotherapy, and a subgroup analysis of patients who underwent systemic chemotherapy multivariate analysis showed that performance status, the presence of liver metastasis and the number of recurrence sites were independently prognostic of cancer-specific and overall survival after relapsing. According to three significant variables, 1- and 3-year cancer-specific survival rates were 72.7% and 20.8% in patients with no risk factors, 46.5% and 7.5% in patients with one risk factor, and 26.4% and 4.4% in patients with two or three risk factors, respectively (P < 0.001). Conclusions Most patients died from UTUC within 3 years, even though systemic chemotherapies were administered after relapsing. Multivariate analysis showed that performance status, the presence of liver metastasis and the number of recurrence sites were independently related to poor survival after systemic chemotherapy.

KW - metastasis

KW - nephroureterectomy

KW - outcome

KW - upper urinary tract

KW - urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84879626350&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84879626350&partnerID=8YFLogxK

U2 - 10.1111/bju.12133

DO - 10.1111/bju.12133

M3 - Article

VL - 112

JO - BJU International

JF - BJU International

SN - 1464-4096

IS - 2

ER -